Skip to main content
OpenTrials
Completed

NCT Number: NCT05843526

Influence of Implant Component Materials on Peri-implant Soft Tissue Horst Response.

The aim of this study was to characterize the host-related response of peri-implant soft tissue induced by 3 different materials: titanium, resin and PEEK (polyetheretherketone) on man.

The primary endpoint is to asses the histological data available: Histological analyses are carried out with immunohistology (CD68, CD3, CD20, macrophages), non decalcified histology to appreciate the structure of the peri implant soft tissues (Sulcus depth, junctional epithelium, connective tissue adhesion).

Moreover: scanning electronic microscope (SEM) of the experimental abutment is performed to juge the cell adhesion on the abutment surface.

The secondary endpoint is to assess clinical data, radiological bone remodeling regarding the different material.

The hypothesis is that resin abutment lead to more inflammation than PEEK or titanium.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital University of Liège (CHU-Ulg)

Liège, 4000, Belgium

About this study

The present study was designed as a randomized controlled trial. A total of 69 implants were placed and experimental abutments made of grade 5 titanium (Ti), dental resin (Optibond ™ FL, Kerr Dental)), polyetheretherketone (PEEK) were randomly allocated to each implant.

Study population: Patients needing tooth replacement in the posterior region (molars) are recruited from the Department of Periodontology and Oral and Implant Surgery of the University of Liege, Belgium.

Procedures

After a local anesthesia, implant procedure is carried out according to the recommendation of the manufacturer while considering the future position of the crown for a screw-retained restoration and the bone anatomy. Then, implants (Bone level or Bone level tapered, SLA active, Straumann Group, Basel, Switzerland) are placed with an insertion torque of at least 20 N/cm. The experimental abutment material is randomly allocated to the implant or two implants when it is possible: Titanium as a group control, PEEK (polyetheretherketone) or resin abutment.

The insertion is made at 15 N/cm and the access hole is obturated with teflon and Telio (Ivoclar vivadent, Schaan, Liechtenstein). A standardized parallel peri-apical radiograph is taken in order to record the baseline bone level. Each patient is instructed to rinse twice daily with an aqueous solution of 0,2% Chlorhexidine (Corsodyl®, GSK, Brentford, United Kingdom) and to avoid brushing of the area until the first recall 10-12 days later. Anti-inflammatories (Ibuprofen® 600 mg) as well as additional analgesics (Paracetamol® 500 mg) are recommended according to the patient's needs. Eight weeks after implantation, the buccal part of the abutment is marked with a drill, and a harvesting guide is placed on the experimental abutment. A punch device cut the soft tissue at 1mm from the abutment surface and both soft tissues and abutment are removed together. When the adherence between soft tissues and abutment is weak (soft tissues slide from the abutment), the abutment is analyzed alone on scanning electronic microscopy and the soft tissues alone are analyzed with immunohistochemistry. When adherence between the abutment and the soft tissues is sufficient, it goes to non decalcified histology. A screw retained abutment or a conventional healing abutment is placed after the harvesting procedure and the prosthetic rehabilitation is performed after 3 months of healing.

Follow-up evaluations and data recording are performed at inclusion visit (baseline), surgery and 8 weeks after implantation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Needing implant therapy
  • One or more missing teeth in the posterior area of either maxilla or mandible
  • Good systemic health (ASA I/II)
  • Full mouth plaque score (FMPI) lower than or equal to 25%
  • The tooth at the implant site(s) had to be extracted or lost at least 12 weeks prior to implant placement
  • 3 mm of keratinized mucosa in the bucco-lingual dimension with bone crest allowing at least a regular diameter implant (4.1 mm).

Exclusion criteria

  • Autoimmune disease requiring medical treatment
  • Medical conditions requiring prolonged use of steroids, use of bisphosphonates and denosumab intravenously or in oral use
  • Pregnancy or breastfeeding women
  • Alcoholism o chronical drug abuse
  • Immunocompromised patients
  • Uncontrolled diabetes
  • Smokers (more than 5 cigs/day)
  • Implant diameter under 4 mm (narrow implant)
  • Infection (systemic or local)
  • The site was excluded if it was previously treated with socket preservation techniques, presented untreated local inflammation, mucosal diseases or oral lesions, history of local irradiation therapy or persistent intraoral infection.

Treatment and study plan

Experimental healing abutment

Device

Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.

Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.

After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment

Primary outcomes

  1. Soft tissue inflammatory response

    Time frame: 8 weeks

    To evaluate the inflammatory response of the peri-implant soft tissue after 8 weeks in contact with the abutment material: Immunohistological analysis of the quantity of macrophages, neutrophils, B and T lymphocytes and blood vessels present in the different samples.

    It has been evaluated using markers: CD3, CD20, CD68, CD34 and counting of marked cells.

    Data are reported with semi quantitative scale.

  2. Characterization of peri implant soft tissues

    Time frame: 8 weeks

    To determine the composition and the length of different parts of the peri implant soft tissues depending on subgingival abutment material (regarding the data of sulcus depth, junctional epithelium and connective tissue in mm) using non decalcified histology.

Secondary outcomes

  1. dental plaque accumulation

    Time frame: 8 weeks

    To assess the amount of plaque present on the abutments with SEM analysis. semi quantitative analyses are performed on the abutment.

  2. Peri-implant bone remodeling

    Time frame: 8 weeks

    Assessment of bone height changes using X-rays Radiographies are analyzed with software ImageJ and mesial and distal values of the bone remodeling (bone line to the implant shoulder) are collected in mm.

  3. Soft tissue health changes assessed by Plaque Index

    Time frame: 8 weeks

    Assessment of plaque percentage

  4. Soft tissue health changes assessed by Keratinized gingiva measure

    Time frame: 8 weeks

    Assessment of height of keratinized mucosa by probing in mm.

  5. Soft tissue health changes assessed by soft tissues height

    Time frame: 8 weeks

    Assessment of height of soft tissue by probing in mm.

Sponsors and collaborators

Lead sponsor

University of Liege

Other

Collaborators

  • ITI International Team for Implantology, Switzerland

Registry information

Official study title

Influence of Implant Component Materials on Peri-implant Soft Tissue Host-response: A Randomized Clinical Trial.

Acronym: PISTI

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
May 6, 2023
Registry last updated
May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.